<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421846</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200306</org_study_id>
    <secondary_id>2020-A00053-36</secondary_id>
    <nct_id>NCT04421846</nct_id>
  </id_info>
  <brief_title>Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis</brief_title>
  <acronym>COLETTE</acronym>
  <official_title>COLETTE : Study of the Pathophysiology of Status Epilepticus and Dysimmune Encephalitis and Identification of Valuable Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem
      tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune
      encephalitis as well as in control patients, to better understand the pathophysiology of
      these severe epileptic disorders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy is one of the most common neurological condition which concerns around 50 million
      people worldwide. Epilepsy is characterized by a lasting predisposition to generate seizures.
      Epilepsy can present as heterogenous set of clinical symptoms and is related to extremely
      varied etiologies. Some epilepsies are triggered by antineuronal autoantibodies and/or
      complicated by a status epilepticus. These conditions may induce brain atrophy, and severe
      neurological sequels.

      The severity of these epilepsies requires significant efforts to (i) identify new therapeutic
      strategies able to control the evolution of dysimmune encephalitis and refractory status
      epilepticus, (ii) to identify their etiologies and (iii) to propose neuroprotective
      strategies.

      Therefore, the investigators will organize a collection of biological samples (blood,
      cerebrospinal fluid, post-mortem brain tissues) and paraclinical data (electroencephalogram,
      evoked potential, CT, MRI) in patients with severe epilepsies, whether or not associated with
      autoantibodies, and/or evolving into status epilepticus.

      This study should bring new insights allowing to better understand mechanisms that trigger
      the emergence of an epileptic brain (epileptogenesis) through :

      (i) the identification and characterization of new pathophysiological pathways involving
      autoimmunity directed against the cerebral cortex and associated with severe epilepsy (ii)
      the identification and characterization of pathophysiological pathways participating in the
      excitotoxicity observed in status epilepticus.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of (i) antibodies in the plasma and in the cerebrospinal fluid of patients with dysimmune encephalitis and (ii) biomarkers for neuronal death in the plasma and in the cerebrospinal fluid of patients with status epilepticus</measure>
    <time_frame>9 months</time_frame>
    <description>Looking for antibodies with cell-based binding assay or monospecific recombinant assay. Identification of biomarkers for neuronal death with electrochemiluminometric sandwich immunoassays (Kryptor and ModularE170, Roche Diagnostic)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of new dysimmune abnormalities</measure>
    <time_frame>9 months</time_frame>
    <description>Lymphocyte phenotyping, cytokines quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of specific EEG patterns associated to dysimmune encephalitis and/or status epilepticus</measure>
    <time_frame>9 months</time_frame>
    <description>EEG signals will be reviewed and classifiyed according to a EEG-based seizure build-up score in status epilepticus (EaSiBUSSEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of new genetic pathways associated to dysimmune encephalitis and status</measure>
    <time_frame>9 months</time_frame>
    <description>Genetic biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of new metabolic pathway that may participate in the excitotoxicity observed in status epilepticus or dysimmune encephalitis</measure>
    <time_frame>9 months</time_frame>
    <description>Looking for diagnostic and prognosis biomarkers. Characterization of the brain cholesterol homeostasis with UPLC-MS/MS method and enzymatic assays. Evaluation of new biomarkers (proteins, lipids, genes).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Status Epilepticus</condition>
  <condition>Dysimmune Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Group 1 : Status epilepticus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : Dysimmune encephalitis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 : Control patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)</intervention_name>
    <description>Collection of biological samples and clinical/paraclinical data</description>
    <arm_group_label>Group 1 : Status epilepticus</arm_group_label>
    <arm_group_label>Group 2 : Dysimmune encephalitis</arm_group_label>
    <arm_group_label>Group 3 : Control patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1:

          -  Patients aged 18 years or above, with status epilepticus.

          -  Affiliation to a French social security system excluding &quot;Aide Médicale&quot; Etat (AME).

          -  Patients or relatives have been informed and given free informed and written consent
             to participate.

        Group 2:

          -  Patients aged 18 years or above, with clinical signs of epilepsy associated to
             dysimmune encephalitis.

          -  Affiliation to a French social security system excluding &quot;Aide Médicale&quot; Etat (AME).

          -  Patients or relatives have been informed and given free informed and written consent
             to participate.

        Group 3:

          -  Patients aged 18 years or above, without status epilepticus and/or dysimmune
             encephalitis.

          -  Affiliation to a French social security system excluding &quot;Aide Médicale&quot; Etat (AME).

          -  Patients or relatives have been informed and given free informed and written consent
             to participate.

        Exclusion Criteria:

        Group 1:

          -  Women with known or clinically detected pregnancy.

          -  Protected adults.

          -  Patients with known neurodegenerative disease.

        Group 2:

          -  Women with known or clinically detected pregnancy.

          -  Protected adults.

          -  Patients have been already treated by corticoids or IgIV.

        Group 3:

          -  Women with known or clinically detected pregnancy.

          -  Protected adults.

          -  Patients with status epilepticus.

          -  Patients with known neurodegenerative disease, brain tumor, severe head trauma,
             meningitis, subarachnoid hemorrhages, stroke.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent NAVARRO, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pitié Salpêtrière - Assitance Publique Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent NAVARRO, Pr</last_name>
    <phone>01 42 16 19 40</phone>
    <email>vincent.navarro@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent NAVARRO, Pr</last_name>
      <phone>01 42 16 19 40</phone>
      <email>vincent.navarro@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Virginie LAMBRECQ, Dr</last_name>
      <phone>01 57 27 46 63</phone>
      <email>virginie.lambrecq@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Status Epilepticus</keyword>
  <keyword>Autoimmunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

